A terminal molybdenum carbide prepared by methylidyne deprotonation

The carbide anion [CMo{N(R)Ar}_3]– [R = C(CD_3)_2CH_3, Ar = C_6H_3Me_2-3,5], is obtained by deprotonation of the corresponding methylidyne compound, [HCMo{N(R)Ar}_3], and is characterized by X-ray diffraction as its {K(benzo-15-crown-5)_2}+ salt, thereby providing precedent for the carbon atom as a terminal substituent in transition-metal chemistry

Ligand design for site-selective installation of Pd and Pt centers to generate homo- and heteropolymetallic motifs

The modular synthesis of a series of nitrogen-rich polydentate ligands that feature a common pincer-type framework is reported. These ligands allow for site-selective installation of palladium and platinum to give rise to bi- and trimetallic complexes that have d^(8)–d^(8) interactions

Detecting Vanishing Dimensions Via Primordial Gravitational Wave Astronomy

Lower-dimensionality at higher energies has manifold theoretical advantages as recently pointed out. Moreover, it appears that experimental evidence may already exists for it - a statistically significant planar alignment of events with energies higher than TeV has been observed in some earlier cosmic ray experiments. We propose a robust and independent test for this new paradigm. Since (2+1)-dimensional spacetimes have no gravitational degrees of freedom, gravity waves cannot be produced in that epoch. This places a universal maximum frequency at which primordial waves can propagate, marked by the transition between dimensions. We show that this cut-off frequency may be accessible to future gravitational wave detectors such as LISA.Comment: Somewhat expanded version with discussions that could not fit into the PRL version; references adde

Phase 1 Safety and Tolerability Study of BMP-7 in Symptomatic Knee Osteoarthritis

BACKGROUND: There are no proven therapies that modify the structural changes associated with osteoarthritis (OA). Preclinical data suggests that intra-articular recombinant human BMP-7 (bone morphogenetic protein-7) has reparative effects on cartilage, as well as on symptoms of joint pain. The objective of this study was to determine the safety and tolerability as well as dose-limiting toxicity and maximal tolerated dose of intra-articular BMP-7. The secondary objectives were to determine the effect on symptomatic responses through 24 weeks. METHODS: This was a Phase 1, double-blind, randomized, multi-center, placebo-controlled, single-dose escalation safety study consisting of 4 dosing cohorts in participants with knee OA. Each cohort was to consist of 8 treated participants, with treatment allocation in a 3:1 active (intra-articular BMP-7) to placebo ratio. Eligible participants were persons with symptomatic radiographic knee OA over the age of 40. The primary objective of this study was to determine the safety and tolerability of BMP-7 including laboratory assessments, immunogenicity data and radiographic assessments. Secondary objectives were to determine the proportion of participants with a 20%, 50%, and 70% improvement in the WOMAC pain and function subscales at 4, 8, 12, and 24 weeks. Other secondary outcomes included the change from baseline to 4, 8, 12, and 24 weeks for the OARSI responder criteria. RESULTS: The mean age of participants was 60 years and 73% were female. All 33 participants who were enrolled completed the study and most adverse events were mild or moderate and were similar in placebo and BMP-7 groups. The 1 mg BMP-7 group showed a higher frequency of injection site pain and there was no ectopic bone formation seen on plain x-rays. By week 12, most participants in both the BMP-7 and placebo groups experienced a 20% improvement in pain and overall the BMP-7 group was similar to placebo with regard to this measurement. In the participants who received 0.1 mg and 0.3 mg BMP-7, there was a trend toward greater symptomatic improvement than placebo. The other secondary endpoints showed similar trends including the OARSI responder criteria for which the BMP-7 groups had more responders than placebo. CONCLUSIONS: There was no dose limiting toxicity identified in this study. The suggestion of a symptom response, together with the lack of dose limiting toxicity provide further support for the continued development of this product for the treatment of osteoarthritis.ARC Future Fellowship; Stryker Biotec

A CO-Derived Iron Dicarbyne That Releases Olefin upon Hydrogenation

An iron diphosphineborane platform that was previously reported to facilitate a high degree of N_2 functionalization is herein shown to effect reductive CO coupling. Disilylation of an iron dicarbonyl precursor furnishes a structurally unprecedented iron dicarbyne complex. Several complexes related to this process are also characterized which allows for a comparative analysis of their respective Fe–B and Fe–C bonding. Facile hydrogenation of the iron dicarbyne at ambient temperature and 1 atm H_2 results in release of a CO-derived olefin

Studies of Cobalt-Mediated Electrocatalytic CO_2 Reduction Using a Redox-Active Ligand

The cobalt complex [Co^(III)N_4H(Br)_2]+ (N_4H = 2,12-dimethyl-3,7,11,17-tetraazabicyclo-[11.3.1]-heptadeca-1(7),2,11,13,15-pentaene) was used for electrocatalytic CO_2 reduction in wet MeCN with a glassy carbon working electrode. When water was employed as the proton source (10 M in MeCN), CO was produced (f_(CO)= 45% ± 6.4) near the Co^(I/0) redox couple for [Co^(III)N_4H(Br)_2]+ (E_(1/2) = −1.88 V FeCp_2^(+/0)) with simultaneous H_2 evolution (f_(H2)= 30% ± 7.8). Moreover, we successfully demonstrated that the catalytically active species is homogeneous through the use of control experiments and XPS studies of the working glassy-carbon electrodes. As determined by cyclic voltammetry, CO_2 catalysis occurred near the formal CoI/0redox couple, and attempts were made to isolate the triply reduced compound (“[Co^0N_4H]”). Instead, the doubly reduced (“Co^I”) compounds [CoN4] and [CoN_4H(MeCN)]+ were isolated and characterized by X-ray crystallography. Their molecular structures prompted DFT studies to illuminate details regarding their electronic structure. The results indicate that reducing equivalents are stored on the ligand, implicating redox noninnocence in the ligands for H_2 evolution and CO_2 reduction electrocatalysis